This Video Is Completely Free To Watch. Simply Enter Your Email Below For Access.
By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works
Disclaimer: This report is for informational and educational purposes only and does not constitute professional financial or investment advice. Furthermore, mentions of specific veterinary therapeutics
The synthesis of this valuation gap requires understanding market dynamics. Investors assign premium multiples to companion animal health businesses (like Idexx Laboratories or the companion
Adyen (ADYEN.AS): A dominant European horizontal player trading at significantly higher growth multiples—commanding a ~5.0x EV/Revenue multiple and ~21.6x forward EV/EBITDA [cite: 1, 2]—largely due
